Four cards, four states, all of them on this deployment at once. Nothing on this screen moves a card from one state to the next, because nothing in this build can: there is no contact-request route, and the consent record a request would write sits on the other side of the wall (DATA-02).
SampleNothing below is a measurement.
Drawn, not measured. ADR 0002 puts aggregation and the release rules in a signal service that neither product has written, so this repository has no signal-event table, no aggregated-signal table and no route that reads one. OncoSkepsis has no deployment either: its first tumour boards run November to December 2026.
Check it: POST /api/signals/ingest on this deployment answers with that refusal, and GET /api/signals/boundary publishes the admissible-field allow-list, which is empty.
pathologist in Greece
sustained interest in KRAS G12C in lung adenocarcinoma
sustained topic signal
NP-15 reads this as the top 1.4 percent of topic scores in the disease area, and that reading stands until the OQ-27 validation study replaces it.
Asking since 2026-W31, still asking in 2026-W38. Weeks, never timestamps: the ISO week is the finest granularity the signal layer keeps (OQ-43).
request sent
No name is shown while a request is outstanding. The request itself is the record, and it names the company that sent it.
No count on this card
There is no weekly figure here and no total, and the card type has no field that could hold one. A count beside one person is that person’s own activity, and no rounding makes a count of one safe to publish (X-12, OQ-14). Counts belong to the topic, where at least 8 different people stand behind every figure that is shown at all. They are on the signal layer overview, beside the weeks the rules withheld.
The consent record
Outcome
pending
Requested
2026-W38
Decided
not yet
Company named in the request
Kalypso Therapeutics
Wording shown, verbatim
Kalypso Therapeutics would like to contact you about your interest in KRAS G12C in lung adenocarcinoma, to ask whether you would join an advisory board. Accepting shares your name and your work email address with Kalypso Therapeutics and with nobody else, and it shares nothing you have asked or answered in OncoSkepsis. Declining changes nothing about your OncoSkepsis access or your tumour boards. You can withdraw an acceptance later in one action, in the place you gave it.
The record keeps the wording as it was shown rather than a summary of it (OQ-42). A record holding a paraphrase would be a record of what the product meant to say, which is not the thing a clinician agreed to. Both dates are weeks, because a consent record is kept at the granularity the signal layer keeps (OQ-43).
A request is outstanding and nothing on the card has changed.
No name, no contact detail and no partial reveal while a decision is pending. The record above is the whole of what exists, and it names the company that asked.
Absent by decision
Anything the clinician asked, typed or answeredOQ-05, DATA-02No question text and no quoted phrase crosses the wall, before an acceptance or after one. A coded topic crosses. The words do not.
An employer, an institution, an avatar or initialsOQ-05, FD-02The card carries profession, country and topic, and its type has no field for any of these, so a screen cannot render one by reaching for it.
Tumour-board membership on a card, a column, a filter or an exportNP-02, OQ-46It appears on the revealed profile after an acceptance, and nowhere before it.
A conflict-of-interest fieldNP-09No field, no flag and no note, on this screen or on any type in this product.
Industry payments, claims and prescribing dataOQ-28Not fetched, not stored and not shown. Absent from the types, not switched off.
A second request after a declineOQ-42The decision is kept and this screen offers no retry, so asking again would have to be something a person does on the record.
Each decision above is in the requirement ledger. The wall itself is not a diagram: hand it a payload at the boundary screener and it names the field, the rule and the requirement.